Article
Oncology
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro
Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.
Article
Hematology
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.
Article
Oncology
Zhongjun Huo, Fang Chen, Ping Liu, Zimian Luo
Summary: This study compares the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatments in newly diagnosed multiple myeloma. The results show that IRd has similar efficacy to VRd, but with better safety and may be more suitable for patients with poor baseline conditions.
Article
Oncology
Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Adam Walter-Croneck, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B. Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study compared the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in patients with newly diagnosed multiple myeloma. The results showed that the combination therapy group had longer progression-free survival compared to the lenalidomide monotherapy group. Further research is needed to confirm these findings.
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Oncology
Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet M. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski
Summary: This study evaluated the addition of ixazomib to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma. The study found that the addition of ixazomib resulted in better progression-free survival compared to lenalidomide alone, and was well tolerated by patients.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman Hajek
Summary: The study compared the efficacy of IRD and RD treatments in patients with multiple myeloma. Results showed that IRD performed better in terms of PFS and OS, especially in specific patient subgroups. Despite not being suitable for certain patients, IRD was found to be a more effective treatment option overall.
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Paul G. Richardson, Shaji K. Kumar, Tamas Masszi, Norbert Grzasko, Nizar J. Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W. Baker, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Laurent Garderet, Cyrille Touzeau, Francis K. Buadi, Jacob P. Laubach, Michele Cavo, Mohamed Darif, Richard Labotka, Deborah Berg, Philippe Moreau
Summary: The TOURMALINE-MM1 study showed that ixazomib-Rd had a significant improvement in progression-free survival compared to placebo-Rd in relapsed or refractory multiple myeloma patients, but the difference in median overall survival between the two groups was not statistically significant. Subgroup analysis indicated a greater benefit in overall survival for patients with adverse prognostic factors, and a higher percentage of patients in the ixazomib-Rd group received proteasome inhibitors as next-line therapy compared to the placebo-Rd group.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Roman Hajek, Jiri Minarik, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G. Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A. Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L. Costello, Faith E. Davies, Vania T. M. Hungria, Hans C. Lee, Xavier Leleu, Noemi Puig, Robert M. Rifkin, Evangelos Terpos, Saad Z. Usmani, Katja C. Weisel, Jeffrey A. Zonder, Magda Barinova, Matyas Kuhn, Jiri Silar, Lenka Capkova, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimir Maisnar
Summary: The study assessed the effectiveness and safety of using Ixazomib-Lenalidomide-Dexamethasone (IRd) in relapsed/refractory multiple myeloma patients, finding comparable results in routine clinical practice to those seen in clinical trials.
Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Helene Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji Kumar
Summary: For multiple myeloma patients, lenalidomide is commonly used as a first-line treatment. However, as patients age, their tolerance to treatment decreases, necessitating alternative options. This study found no significant difference in efficacy between ixazomib-dexamethasone and pomalidomide-dexamethasone, suggesting that ixazomib-dexamethasone can be an important lenalidomide-free oral option for heavily pretreated, lenalidomide-refractory patients exposed to proteasome inhibitors.
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Teruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Aya Nakaya, Shin-ichi Fuchida, Hirohiko Shibayama, Mitsuhiro Matsuda, Yutaka Shimazu, Yoko Adachi, Satoru Kosugi, Hitoji Uchiyama, Hirokazu Tanaka, Hitoshi Hanamoto, Yuji Shimura, Junya Kanda, Yoshiyuki Onda, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Summary: The study investigated real-world data of IRd therapy for RRMM patients, with a median age of 72 and most patients having IgG type. The median number of prior therapies was 4, mainly comprising bortezomib and lenalidomide-based regimens. Disease progression and adverse events were common reasons for treatment discontinuation. The study found that lenalidomide-refractory patients had significantly lower PFS than lenalidomide-sensitive patients, and the patients with IgG type had significantly better PFS and OS. Overall, IRd showed poor efficacy in non-IgG type and lenalidomide-refractory patients with RRMM in real clinical practice.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Review
Health Care Sciences & Services
Catalin Constantinescu, Bobe Petrushev, Ioana Rus, Horia Stefanescu, Otilia Frasinariu, Simona Margarit, Delia Dima, Ciprian Tomuleasa
Summary: Hemophagocytic lymphohistiocytosis is a rare and life-threatening condition that requires thorough diagnosis and early treatment. Its development is associated with hematological malignancies, para-neoplastic syndromes, or infections related to immune system deficiency.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Javier de la Rubia, Bernardo Gonzalez, Alfonso J. Cruz-Jentoft, Lorena Iglesias, Isidro Jarque, Ernesto Perez Persona, Rafael Lluch, Carmen Marrero, Maite Zudaire, Mercedes Gironella, Jose Angel Hernandez-Rivas, Montserrat Arnan, Carmen Olivier, Cristina Encinas, Juan Alfonso Soler, Angel Ramirez Payer, Alfonso Casado, Patricia Fernandez, David Vilanova, Santiago Bonanad
Summary: The GAH scale is a valid tool to identify older patients with hematological malignancies at higher risk of treatment-related toxicity. This study determined the weights for each dimension of the GAH scale and the cut-off point to predict treatment tolerability in this population. The results showed that the GAH total score of 42 was the optimal cut-off value.
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Esther Clavero, Jose Manuel Sanchez-Maldonado, Angelica Macauda, Rob Ter Horst, Belem Sampaio-Marques, Artur Jurczyszyn, Alyssa Clay-Gilmour, Angelika Stein, Michelle A. T. Hildebrandt, Niels Weinhold, Gabriele Buda, Ramon Garcia-Sanz, Waldemar Tomczak, Ulla Vogel, Andres Jerez, Daria Zawirska, Marzena Watek, Jonathan N. Hofmann, Stefano Landi, John J. Spinelli, Aleksandra Butrym, Abhishek Kumar, Joaquin Martinez-Lopez, Sara Galimberti, Maria Eugenia Sarasquete, Edyta Subocz, Elzbieta Iskierka-Jazdzewska, Graham G. Giles, Malwina Rybicka-Ramos, Marcin Kruszewski, Niels Abildgaard, Francisco Garcia Verdejo, Pedro Sanchez Rovira, Miguel Inacio da Silva Filho, Katalin Kadar, Malgorzata Razny, Wendy Cozen, Matteo Pelosini, Manuel Jurado, Parveen Bhatti, Marek Dudzinski, Agnieszka Druzd-Sitek, Enrico Orciuolo, Yang Li, Aaron D. Norman, Jan Maciej Zaucha, Rui Manuel Reis, Miroslaw Markiewicz, Juan Jose Rodriguez Sevilla, Vibeke Andersen, Krzysztof Jamroziak, Kari Hemminki, Sonja I. Berndt, Vicent Rajkumar, Grzegorz Mazur, Shaji K. Kumar, Paula Ludovico, Arnon Nagler, Stephen J. Chanock, Charles Dumontet, Mitchell J. Machiela, Judit Varkonyi, Nicola J. Camp, Elad Ziv, Annette Juul Vangsted, Elizabeth E. Brown, Daniele Campa, Celine M. Vachon, Mihai G. Netea, Federico Canzian, Asta Foersti, Juan Sainz
Summary: By conducting a meta-analysis on the germline genetic data of 234 autophagy-related genes from three independent study populations, we investigated the influence of autophagy-related variants on the risk of Multiple Myeloma (MM) and examined the functional mechanisms behind the observed associations. We identified SNPs within the six CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A loci associated with MM risk and found that their effect on disease risk was mediated by specific subsets of immune cells, as well as vitamin D3-, MCP-2-, and IL20-dependent mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Leire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, Maria-Teresa Cedena, Camila Guerrero, Tomas Jelinek, Sarah Johnson, Paolo Milani, Lourdes J. Cordon, Jose Perez, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernandez, Luis Palomera, Rafael Martinez-Martinez, Javier de la Rubia, Felipe de Arriba, Rafael Rios, Maria-Esther Gonzalez, Mercedes Gironella, Valentin Cabanas, Maria Casanova, Isabel Krsnik, Albert Perez-Montana, Veronica Gonzalez-Calle, Paula Rodriguez-Otero, Vladimir Maisnar, Roman Hajek, Fritz Van Rhee, Victor Jimenez-Zepeda, Giovanni Palladini, Giampaolo Merlini, Alberto Orfao, Javier de la Cruz, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosinol, Joan Blade, Maria-Victoria F. Mateos, Jesus San-Miguel, Bruno Paiva
Summary: An algorithm to identify patients with MGUS-like phenotype in multiple myeloma (MM) and light-chain (AL) amyloidosis was developed and its clinical significance was validated. The presence of MGUS-like phenotype in smoldering MM was associated with lower rates of disease progression, while in newly diagnosed active MM, it retained independent prognostic value in terms of progression-free survival (PFS) and overall survival (OS). The algorithm also predicted different survival outcomes in patients with AL amyloidosis.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosinol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt
BLOOD CANCER JOURNAL
(2023)
Article
Immunology
Ana Jimenez-Ubieto, Alejandro Martin-Munoz, Maria Poza, Sara Dorado, Almudena Garcia-Ortiz, Enrique Revilla, Pilar Sarandeses, Yanira Ruiz-Heredia, Tycho Baumann, Antonia Rodriguez, Maria Calbacho, Pilar Martinez Sanchez, Jose Maria Sanchez Pina, Alejandro Martin Garcia-Sancho, Gloria Figaredo, Laura Rufian, Margarita Rodriguez, Laura Carneros, Carolina Martinez-Laperche, Mariana Bastos-Oreiro, Chongwu Wang, Maria-Teresa Cedena, Inmaculada Rapado, Paula de Toledo, Antonio Valeri, Rosa Ayala, Joaquin Martinez-Lopez, Santiago Barrio
Summary: This study investigates the potential value of ctDNA monitoring in FL patients treated with CAR T-cell therapy. The results suggest that non-invasive liquid biopsy MRD analysis can correlate with treatment response and be used for monitoring response.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Oncology
N. Lopez-Munoz, G. Hernandez-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jimenez, R. Iniguez, M. Pedrera, J. Cruz, L. Meloni, D. Perez-Rey, P. Serrano, J. de la Cruz, J. Martinez-Lopez
Summary: Survival in multiple myeloma has improved significantly in recent years, especially in young patients. A study conducted at 12 de Octubre Hospital and validated using TriNetx data found differences in survival rates and treatment patterns among patients from different time periods and regions.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Medicine, General & Internal
Carlos Solano, Pedro Castro-Rebollo, Antonio Perez-Martinez, Lucia Lopez-Corral, Pere Barba-Sunol, Mi Kwon, Valentin Ortiz, Jaime Sanz-Caballer, Ana Carolina Caballero, Joaquin Martinez, Angel Cedillo, Anna Sureda
Summary: This study estimated the readiness of Spanish NHS hospitals to provide CAR-T therapy and identified and quantified the resources needed. It found that only four hospitals were fully ready, while 17 were somewhat ready and seven were not ready. The numbers of hematologists, nurses, and beds were identified as the most important limiting factors.
Article
Pharmacology & Pharmacy
Alberto Blanco Sanchez, Rodrigo Gil Manso, Gonzalo Carreno-Tarragona, Diana Paredes Ruiz, Jesus Gonzalez Olmedo, Joaquin Martinez-Lopez, Carmen Diaz Pedroche, Rosa Ayala
Summary: This study demonstrates the importance of assessing cardiovascular risk and effectively managing risk factors in patients with CML treated with tyrosine kinase inhibitors. Follow-up in a specialized cardiovascular risk consultation can lead to a reduction in cardiovascular adverse events and improve patients' overall cardiovascular health.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Luis Gerardo Rodriguez-Lobato, Natalia Tovar, Anna de Daniel, Carlos Fernandez de Larrea, M. Teresa Cibeira, Raquel Jimenez-Segura, David F. Moreno, Aina Oliver-Caldes, Joan Blade, Laura Rosinol
Summary: This study analyzed the reasons for exclusion of non-transplant-eligible newly diagnosed multiple myeloma (NDMM) patients from clinical trials (CTs) and their prognosis. The findings showed that comorbidities and worsened ECOG were the main reasons for CT exclusion, and patients included in CTs had a longer overall survival (OS) compared to those receiving non-trial treatment (NCT).
Article
Hematology
Karthik Ramasamy, Herve Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquin Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W. C. J. van de Donk, Katja Weisel
Summary: We conducted a modified Delphi study to identify areas of consensus and nonconsensus on the use of measurable residual disease (MRD) testing in multiple myeloma (MM) treatment response. The study included two rounds of surveys with 61 expert hematological oncologists from 14 European countries. The experts reached consensus on the importance of MRD testing in certain clinical situations and provided recommendations on when and how to perform the testing.
Article
Hematology
Karthik Ramasamy, Herve Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquin Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W. C. J. van de Donk, Katja Weisel
Summary: We used a modified Delphi approach to establish consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) in multiple myeloma (MM) treatment response, which may inform disease management and future clinical trial design.
Meeting Abstract
Transplantation
Marc Patricio Liebana, Alicia Senin, Maria Azancot, Mercedes Gironella, Nestor Toapanta Gaibor, Sheila Bermejo Garcia, Lucia Martin, Fernando Caravaca-Fontan, Clara Cuellar Perez-Avila, Joaquin Martinez-Lopez, Eva Rodriguez-Garcia, Oriol Bestard Matamoros, Maria Jose Soler Romeo, Natalia Ramos Terrades
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)